ArticleDrugs - real world outcomes2026

Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.

Dayoung Seo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.